Citadel Advisors
BCAX

Citadel Advisors’s Bicara Therapeutics BCAX Stock Holding History

Citadel Advisors’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.27M Sell
211,142
-1,448,200
-87% -$32.3M ﹤0.01% 4332
2026
Q1 		$33M Buy
1,659,342
+887,084
+115% +$15.3M 0.01% 1759
2025
Q4 		$13M Buy
+772,258
New +$13.2M ﹤0.01% 2895
2025
Q3 		– Sell
-221,516
Closed -$2.06M – 14442
2025
Q2 		$2.06M Buy
+221,516
New +$2.64M ﹤0.01% 5653
2024
Q4 		– Sell
-234,122
Closed -$5.96M – 15591
2024
Q3 		$5.96M Buy
+234,122
New +$5.97M ﹤0.01% 3666

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors's BCAX Position: Q2 2026 in Review

Citadel Advisors reduced its Bicara Therapeutics (BCAX) stake by 87% in Q2 2026, selling an estimated $32.3M and leaving 211,142 shares worth $6.27M. The position accounts for ﹤0.01% of the portfolio, ranked #4332.

Citadel Advisors first reported a position in BCAX in Q3 2024 and has held it in 5 quarters since. The position peaked at $33M in Q1 2026. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Citadel Advisors held 211,142 shares of Bicara Therapeutics worth $6.27M as of Q2 2026.
  • Citadel Advisors sold 1,448,200 Bicara Therapeutics shares in Q2 2026, an estimated $32.3M.
  • Bicara Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4332 holding.
  • Citadel Advisors first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • Citadel Advisors's Bicara Therapeutics position peaked at $33M in Q1 2026.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.